The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV

References

• Alvar, J., Carlavate, C., Gutierrez-Solar, B., Jimenez, M., Laguna, F., Lopez-Velez, R., Molina, R. & Moreno, J. (1997). Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clinical Microbiology Reviews, 10, 298–319
   PubMed Web of Science ®Google Scholar
• Amador, C., Bodi, V., Pasquau, F., Ena, J., Benito, C. & Fenoll, V. (2001). Factores de riesgo asociados a la aparición de infecciones durante el primer alio de tratamiento antirretroviral de alta eficacia. Medicina Clinica, 116, 41–46.
   PubMedGoogle Scholar
• Anon. (1999). Enfermedades de declaraciOn obligatoria, 1998. Boletin Epidemiológico de la Comunidad de Madrid, 6, 11–31.
   Google Scholar
• Berenguer, J., Cosin, J., Miralles, P., Lopez, J. C. & Padilla, B. (2000). Discontinuation of secondary anti-Leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. AIDS, 14, 2946–2948.
   PubMed Web of Science ®Google Scholar
• Casado, J., López-Velez, R., Pintado, V., Antela, A., Quereda, C. & Moreno, S. (2001). Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy. European Journal of Clinical Microbiology and Infectious Diseases, 20, 202–205.
   PubMed Web of Science ®Google Scholar
• Clerici, M., Hakim, F. T., Venzon, D. J., Blatt, S., Hendrix, C. W., Wynn, T. A. & Shearer, G. M. (1993). Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immuno-deficiency virus-seropositive individuals. Journal of Clinical Investigation, 91, 759–765.
   PubMed Web of Science ®Google Scholar
• De la Rosa, R., Pineda, J. A., Delgado, J., Macias, J., Morillas, F., Martin-Sanchez, J., Leal, M., Sanchez-Quijano, A. & Lissen, E. (2001). Influence of highly active antiretroviral therapy on the outcome of sub-clinical visceral leishmaniasis in human immuno-deficiency virus-infected patients. Clinical Infectious Diseases, 32, 633–635.
   PubMed Web of Science ®Google Scholar
• Di Giorgio, C., Faraut-Gambarelli, F., Imbert, A., Minodier, P., Gasquet, M. & Dumon, H. (1999). Flow cytometric assessment of amphotericin B susceptibility in Leishmania infantum isolates from patients with visceral leishmaniasis. Journal of Anti-microbial Chemotherapy, 44, 71–76.
   PubMed Web of Science ®Google Scholar
• Faraut-Gambarelli, F., Piarroux, R., Deniau, M., Giusiano, B., Marty, P., Michel, G., Faugere, B. & Dumon, H. (1997). In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrobial Agents and Chemotherapy, 41, 827–830.
   PubMed Web of Science ®Google Scholar
• Jimenez-Expósito, M., Alonso-Villaverde, C., Sardd, P. & Masana, L. (1999). Visceral leishmaniasis in HIV-infected patients with non-detectable HIV-viral load after highly active antiretroviral therapy. AIDS, 13, 152–153.
   PubMed Web of Science ®Google Scholar
• Kubar, J., Marty, P., Lelievre, A., Quaranta, J. F., Staccini, P., Caroli-Bosc, C. & Le Fichoux, Y. (1998). Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4 + T-lymphocyte counts. AIDS, 12, 2147–2153.
   PubMed Web of Science ®Google Scholar
• Laguna, F., Adrados, M., Alvar, J., Soriano, V., Valencia, M. E., Moreno, V., Polo, R., Verdejo, J., Jimenez, M. I., Martinez, P., Martinez, M. L. & Gonzhlez-Lahoz, J. M. (1997). Visceral leishmaniasis in patients infected with the human immuno-deficiency virus. European Journal of Clinical Micro-biology and Infectious Diseases, 16, 898–903.
   PubMed Web of Science ®Google Scholar
• Laguna, F., López-Velez, R., Pulido, F., Salas, A., Torre-Cisneros, J., Torres, E., Medrano, F. J., Sanz, J., Pico, G., Gomez-Rodrigo, J., Pasquau, J. & Alvar, J. (1999). Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial com-paring meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS, 13, 1063–1069.
   Google Scholar
• López-Vélez, R., Perez-Molina, J. A., Guerrero, A., Baquero, F., Villarrubia, J., Escribano, L., Bellas, C., Perez-Corral, F. & Alvar, J. (1998). Clinico-epidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. American Journal of Tropical Medicine and Hygiene, 58, 436–443.
   PubMed Web of Science ®Google Scholar
• López-Vélez, R., Casado, J. & Pintado, V. (2001). Decline of a visceral leishmaniasis epidemic in HIV-infected patients after the introduction of highly active antiretroviral therapy (HAART). Clinical Microbiology and Infection, 7,394–395.
   PubMed Web of Science ®Google Scholar
• Mastroianni, C. M., d'Ettorre, G., Forcina, G., Corpolongo, A., dell'Isola, S., Lichtner, M., d'Agostino, C., Trinchieri, V., Santopadre, P. & Vullo, V. (2000). Long-term remission of human immunodeficiency virus-associated visceral leish-maniasis after initiation of potent combination anti-retroviral treatment: report of two cases. Journal of Infection, 40, 94–96.
   Google Scholar
• Medrano, F. J., Rey, C., Leal, M., Carlavate, C., Rubio, A., Sanchez-Quijano, A., Alvar, J. & Lissen, E. (1998). Dynamics of serum cytokines in patients with visceral leishmaniasis and HIV-1 co-infection. Clinical and Experimental Immunology, 114, 403–407.
   PubMed Web of Science ®Google Scholar
• Miralles, P., Moreno, S., Pérez-Tascón, M., Cosin, J., Diaz, M. D. & Bouza, E. (1995). Fever of uncertain origin in patients infected with the human immuno-deficiency virus. Clinical Infectious Diseases, 20, 872–875.
   PubMed Web of Science ®Google Scholar
• Nigro, L., Cacopardo, B., Preiser, W., Braner, J., Cinatl, J., Palermo, F., Russo, R., Doerr, H. W. & Nunnari, A. (1999). In vitro production of type 1 and type 2 cytokines by peripheral blood mono-nuclear cells from subjects coinfected with human immunodeficiency virus and Leishmania infantum. American Journal of Tropical Medicine and Hygiene, 60, 142–145.
   PubMed Web of Science ®Google Scholar
• Pérez-Molina, J. A., Lopez-Velez, R., Montilla, P. & Guerrero, A. (1996). Pentamidine isothionate as secondary prophylaxis against visceral leishmaniasis in HIV-positive patients. AIDS, 10, 237–238.
   PubMed Web of Science ®Google Scholar
• Pintado, V. & López-Velez, R. (2001). HIV-associated visceral leishmaniasis. Clinical Microbiology and Infection, 7,291–300.
   PubMed Web of Science ®Google Scholar
• Pintado, V., Martin-Rabadán, P., Rivera, M. L., Moreno, S. & Bouza, E. (2001). Visceral leish-maniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A com-parative study. Medicine, 80, 54–73.
   PubMed Web of Science ®Google Scholar
• Ribera, E., Ocaria, I., de Otero, J., Cortes, E., Gasser, I. & Pahissa, A. (1996). Prophylaxis of visceral leish-maniasis in human immunodeficiency virus-infected patients. American Journal of Medicine, 100, 496–501.
   PubMed Web of Science ®Google Scholar
• Ridolfo, A. L., Gervasoni, C., Antinori, S., Pizzuto, M., Santambrogio, S., Trabattoni, D., Clerici, M. & Galli, M. (2000). Post-kala-azar dermal leishmaniasis during highly active antiretroviral therapy in an AIDS patient infected with Leishmania infantum. Journal of Infection, 40, 199–202.
   PubMed Web of Science ®Google Scholar
• Soriano, V., Dona, C., Rodriguez-Rosado, R., Barreiro, P. & Gonzhlez-Lahoz, J. (2000). Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active anti-retroviral therapy. AIDS, 14, 383–386.
   PubMed Web of Science ®Google Scholar
• Tumbarello, M., Tacconelli, E., Bertagnolio, S. & Cauda, R. (2000). Highly active antiretroviral therapy decreases the incidence of visceral leishmaniasis in HIV-infected individuals. AIDS, 14, 2948–2950.
   PubMed Web of Science ®Google Scholar
• Villanueva, J., AlarcOn, A., Bernabeu-Wittel, M., Cordero, E., Prados, D., Regordin, C. & Alvar, J. (2000). Prospective evaluation and follow-up of euro-pean patients with visceral leishmaniasis and HIV-1 coinfection in the era of highly active antiretroviral therapy. European Journal of Clinical Microbiology and Infectious Diseases, 19, 798–801.
   PubMed Web of Science ®Google Scholar
• World Health Organization (1995). Report on the Consultative Meeting on Leishmania/HIV Co-infection. Document WHO/LEISH/95/1-14. Geneva: WHO.
   Google Scholar
• World Health Organization (1999). LeishmanialHIV co-infection, south-western Europe, 1990-1998. Weekly Epidemiological Record, 74,365–375.
   PubMedGoogle Scholar